STUDY OF CLINICAL AND PATHOGENETIC EFFECTS OF ANTI-VIRAL DRUG BASED ON FAVIPIRAVIR IN COMORBID PATIENTS WITH COVID-19 AT THE OUTPATIENT STAGE OF TREATMENT
In many ways, arterial hypertension and obesity determine the likelihood of a severe course and lethal outcomes in COVID-19. This fact justifies the expediency of an early use of drugs with a direct antiviral action, the analysis of their efficacy not only in the acute, but also in the postcovid per...
Saved in:
Main Authors: | L. A. Balykova (Author), O. A. Radaeva (Author), K. Ya. Zaslavskaya (Author), Yu. A. Kostina (Author), M. S. Iskandyarova (Author), E. V. Negodnova (Author), V. V. Eremeev (Author), L. F. Sabirov (Author), E. V. Semeleva (Author) |
---|---|
Format: | Book |
Published: |
Volgograd State Medical University, Pyatigorsk Medical and Pharmaceutical Institute,
2021-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
STUDY OF LONG-TERM CLINICAL AND PATHOGENETIC EFFECTS OF FAVIPIRAVIR-BASED ANTI-VIRAL DRUG IN PATIENTS WITH METABOLIC SYNDROME IN POST-COVID PERIOD
by: O. A. Radaeva, et al.
Published: (2022) -
A clinical case of autosomal recessive agammaglobulinemia with B-cell deficiency
by: E. V. Negodnova, et al.
Published: (2024) -
EFFECTIVENESS AND SAFETY OF FAVIPIRAVIR INFUSION IN PATIENTS HOSPITALIZED WITH COVID-19
by: L. A. Balykova, et al.
Published: (2022) -
Pathogenetic treatment of patients with COVID-19 at the outpatient stage
by: M.M. Ostrovskyi, et al.
Published: (2022) -
Pathogenetic justification of sacubitril / valsartan use in respiratory-cardial comorbidity
by: T. V. Ashcheulova, et al.
Published: (2023)